April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Mutation screening in patients with retinal dystrophies using a Panel-based Next Generation Sequencing approach
Author Affiliations & Notes
  • Nicole Weisschuh
    Institute for Ophthalmic Research, Tuebingen, Germany
  • Anja-Kathrin Mayer
    Institute for Ophthalmic Research, Tuebingen, Germany
  • Nicola Gloeckle
    CeGaT GmbH, Tuebingen, Germany
  • Susanne Kohl
    Institute for Ophthalmic Research, Tuebingen, Germany
  • Saskia Biskup
    CeGaT GmbH, Tuebingen, Germany
  • Bernd Wissinger
    Institute for Ophthalmic Research, Tuebingen, Germany
  • Footnotes
    Commercial Relationships Nicole Weisschuh, None; Anja-Kathrin Mayer, None; Nicola Gloeckle, CeGaT GmbH (E); Susanne Kohl, None; Saskia Biskup, None; Bernd Wissinger, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3268. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nicole Weisschuh, Anja-Kathrin Mayer, Nicola Gloeckle, Susanne Kohl, Saskia Biskup, Bernd Wissinger; Mutation screening in patients with retinal dystrophies using a Panel-based Next Generation Sequencing approach. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3268.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Retinal dystrophies (RD) constitute a group of blinding diseases that are characterized by clinical variability and pronounced genetic heterogeneity. The different forms of RD can be attributed to mutations in more than 100 genes. Consequently, next generation sequencing (NGS) technologies are among the most promising approaches to identify mutations in RD. We screened 57 patients with different forms of RD (autosomal recessive and autosomal dominant Retinitis Pigmentosa, cone dystrophies, cone-rod dystrophies and Achromatopsia) in a research context for mutations in 105 RD-associated genes using hybridization-based enrichment and SOLiD-based NGS. Most of these patients had been tested negative upon screening for mutations in frequently affected genes applying Sanger Sequencing and/or high throughput mutation microarrays (Asper chips).

Methods: All putative disease-associated variants identified by our NGS approach were validated and tested for segregation with the phenotype in available family members by Sanger sequencing. In addition, exons with a coverage less than 10 reads of the NGS data were analyzed by Sanger sequencing. Whole exon deletions were validated by duplex PCR.

Results: In total, we detected mutations in 20 different RD genes. Mutations explaining the disease phenotype were identified in 29 cases. In the remaining 28 patients, we did not detect sequence alterations that explain the disease phenotype. Among these, we found several autosomal recessive cases that carry sequence alterations in one of the frequently affected genes (e.g. USH2A or ABCA4), but lack a second clearly pathogenic variant. It cannot be excluded that deep intronic variants exist which were not detected due to the targeted enrichment of the exonic regions for NGS-based genetic testing. Another explanation is of course that these patients harbor mutations in yet unknown disease-genes. To elucidate this, we are currently analyzing the unsolved cases by whole-exome-sequencing.

Conclusions: To summarize, we used a targeted resequencing approach in a genetically pre-selected cohort of patients with RD and were able to identify causative mutations in 51% of cases. Non-solved cases are promising candidates for the identification of novel disease-genes using whole-exome sequencing.

Keywords: 648 photoreceptors • 539 genetics • 604 mutations  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.